Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $339.50 USD
Change Today +12.52 / 3.83%
Volume 4.1M
AGN On Other Exchanges
New York
As of 8:04 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

allergan plc (AGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/28/15 - $340.00
52 Week Low
08/12/14 - $201.91
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ALLERGAN PLC (AGN)

allergan plc (AGN) Details

Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. The North American Brands segment provides patented and off-patent trademarked pharmaceutical products primarily under the Dalvance, Bystolic, Canasa, Carafate, Daliresp, Fetzima, Linzess, Namenda, Namenda XR, Saphris, Teflaro, Viibryd, Actonel, Asacol HD, Atelvia, Delzicol, Doryx, Estrace Cream, Enablex, Lo Loestrin Fe, and Minastrin 24 Fe brands. The North American Generics and International segment develops, manufactures, and sells generic, branded generic, and OTC pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products primarily to independent pharmacies, pharmacy chains and buying groups, and physician’s offices. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, gastroenterology, urology, and dermatology areas. The company sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers, and distributors, including national retail drug and food store chains, hospitals, clinics, mail order retailers, government agencies, and managed healthcare providers. It has a collaboration agreements with Amgen, Inc. to develop and commercialize biosimilar versions of Herceptin, Avastin, Rituxan/Mab Thera, and Erbitux; Ironwood Pharmaceuticals to develop and commercialize Linzessfor the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; Sanofi-Aventis U.S. LLC; and Trevena for the development of TRV027. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Parsippany, New Jersey.

21,600 Employees
Last Reported Date: 02/18/15
Founded in 1983

allergan plc (AGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $500.0K
Executive Chairman
Total Annual Compensation: $1.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $31.4K
Executive Vice President and President of Gen...
Total Annual Compensation: $707.5K
Executive Vice President and President of Bra...
Total Annual Compensation: $272.5K
Compensation as of Fiscal Year 2014.

allergan plc (AGN) Key Developments

Allergan plc, Teva Pharmaceutical Industries Limited - M&A Call

To discuss the definitive agreement under which Teva Pharmaceutical Industries Ltd. will acquire Allergan's global generic pharmaceuticals business for $40.5 billion

Allergan plc, Teva Pharmaceutical Industries Limited - M&A Call

To discuss about the definitive agreement with Allergan plc to acquire Allergan Generics in a transaction valued at $40.5 billion

Allergan Mulls Acquisitions

Allergan plc (NYSE:AGN) is seeking acquisitions. Brent Saunders, Chief Executive of Allergan said, “The company will use the $36 billion in net proceeds from the generics sale to help fund further large acquisitions. We can accelerate our timing on transformational M&A.” Brent Saunders cited aesthetics, eye care, central nervous system disorders and gastrointestinal therapies as areas for potential future deals.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGN:US $339.50 USD +12.52

AGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $172.74 USD +7.20
Bristol-Myers Squibb Co $64.66 USD +0.36
Celgene Corp $135.42 USD +2.86
Medtronic PLC $77.47 USD +1.81
Novo Nordisk A/S kr397.70 DKK +4.70
View Industry Companies

Industry Analysis


Industry Average

Valuation AGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.5x
Price/Book 1.9x
Price/Cash Flow 149.3x
TEV/Sales 5.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLERGAN PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at